Last updated: 07/17/2024 15:06:25
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy TrialSTABILITY
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Trial description: This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of participants with first occurrence of any component of the composite of major adverse cardiovascular events (cardiovascular [CV] death, non-fatal myocardial infarction [MI] or non-fatal stroke) during the time period for follow-up of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Secondary outcomes:
Number of participants with first occurrence of any event in the composite of major coronary events (coronary heart disease [CHD] death, non-fatal MI, or urgent coronary revascularization [CR] for MI) during the time period for follow-up (FU) of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with first occurrence of any event in the composite of total coronary events (CHD death, non-fatal MI, hospitalization for unstable angina, or any coronary revascularization procedure) during time period for FU of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with CV death during the time period for follow-up of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with first occurrence of MI (fatal/non-fatal) during the time period for follow-up of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with first occurrence of stroke (fatal/non-fatal) during the time period for follow-up of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with first occurrence of any component of the composite of all-cause mortality, non-fatal MI, or non-fatal stroke during the time period for follow-up of CV events
Timeframe: From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of participants with all-cause mortality during the time period for vital status
Timeframe: From randomization until death or study completion (up to 4.49 years/average of 3.65 years)
Interventions:
Enrollment:
15828
Primary completion date:
2013-17-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
The STABILITY Investigators.Effect of Darapladib on Prevention of Ischemic Events in Stable Coronary Heart Disease.N Engl J Med.2014;370(18):1702-1711
Matthias Wuttke et al (200+ authors).A catalogue of molecular targets for kidney function from genetic 1 analyses of a million individuals.Nat Genet.2019;51:957–972
DOI: 10.1038/s41588-019-0407-x
Medical condition
Atherosclerosis
Product
darapladib
Collaborators
Not applicable
Study date(s)
December 2008 to October 2013
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Men or women at least 18 years old. Women must be post-menopausal or using a highly
- effective method for avoidance of pregnancy.
- Planned coronary revascularization (such as stent placement or heart bypass) or any other major
- surgical procedure.
Inclusion and exclusion criteria
Inclusion criteria:
- Men or women at least 18 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
- Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject.
- Chronic coronary heart disease
- At least one of the following:
- At least 60 years old
- Diabetes requiring treatment with medication
- Low HDL cholesterol ("good cholesterol")
- Currently smoke cigarettes or stopped smoking within the past 3 months
- Diagnosed mild or moderate reduction in kidney function
- Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease.
Exclusion criteria:
- Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure.
- Liver disease
- Severe reduction in kidney function OR removal of a kidney OR kidney transplant
- Severe heart failure
- Blood pressure higher than normal despite lifestyle changes and treatment with medications
- Any life-threatening disease expected to result in death within the next 2 years (other than heart disease)
- Severe asthma that is poorly controlled with medication
- Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to study entry)
- Previous severe allergic response to food, drink, insect stings, etc.
- Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
- Certain medications that may interfere with the study medication (these will be identified by the study doctor)
- Participation in a study of an investigational medication within the past 30 days
- Current participation in a study of an investigational device
Trial location(s)
Location
GSK Investigational Site
Adrogue, Buenos Aires, Argentina, B1846DSK
Status
Study Complete
Location
GSK Investigational Site
Aix en Provence cedex 1, France, 13616
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87102
Status
Study Complete
Location
GSK Investigational Site
Anchorage, Alaska, United States, 99508
Status
Study Complete
Location
GSK Investigational Site
Atlantis, Florida, United States, 33462
Status
Study Complete
Location
GSK Investigational Site
Auchenflower, Queensland, Australia, 4066
Status
Study Complete
Location
GSK Investigational Site
Aurora, Illinois, United States, 60504
Status
Study Complete
Location
GSK Investigational Site
Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32545
Status
Study Complete
Location
GSK Investigational Site
Bahia Blanca, Buenos Aires, Argentina, B8000FTD
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21209
Status
Study Complete
Location
GSK Investigational Site
Bay Roberts, Newfoundland and Labrador, Canada, A0A 1G0
Status
Study Complete
Location
GSK Investigational Site
Beaver, Pennsylvania, United States, 15009
Status
Study Complete
Location
GSK Investigational Site
Bedford Park, South Australia, Australia, 5042
Status
Study Complete
Location
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30150-221.
Status
Study Complete
Location
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30380090
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35235
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35294-0007
Status
Study Complete
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02111
Status
Study Complete
Location
GSK Investigational Site
Bridgeport, Connecticut, United States, 06606
Status
Study Complete
Location
GSK Investigational Site
Bridgeport, Connecticut, United States, 06610
Status
Study Complete
Location
GSK Investigational Site
Bristol, Tennessee, United States, 37620
Status
Study Complete
Location
GSK Investigational Site
Browns Mills, New Jersey, United States, 08015
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, 1425
Status
Study Complete
Location
GSK Investigational Site
Buffalo, New York, United States, 14215
Status
Study Complete
Location
GSK Investigational Site
CABA, Buenos Aires, Argentina, C1124AAJ
Status
Study Complete
Location
GSK Investigational Site
Cadillac, Michigan, United States, 49601
Status
Study Complete
Location
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Status
Study Complete
Location
GSK Investigational Site
Caulfield South, Victoria, Australia, 3162
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29401
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29425-6240
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28204
Status
Study Complete
Location
GSK Investigational Site
Chelsea, London, United Kingdom, SW3 6NP
Status
Study Complete
Location
GSK Investigational Site
Chertsey, Surrey, United Kingdom, KT16 0PZ
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60654
Status
Study Complete
Location
GSK Investigational Site
Chichester, Sussex West, United Kingdom, PO19 4SE
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45227
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45246
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1125ABD
Status
Study Complete
Location
GSK Investigational Site
Coffs Harbour, New South Wales, Australia, 2450
Status
Study Complete
Location
GSK Investigational Site
Colorada Springs, Colorado, United States, 80920
Status
Study Complete
Location
GSK Investigational Site
Cona (Ferrara), Emilia-Romagna, Italy, 44124
Status
Study Complete
Location
GSK Investigational Site
Concord, New South Wales, Australia, 2139
Status
Study Complete
Location
GSK Investigational Site
Concord, California, United States, 94520
Status
Study Complete
Location
GSK Investigational Site
Conyers, Georgia, United States, 30094
Status
Study Complete
Location
GSK Investigational Site
Corpus Christi/Texas, Texas, United States, 78404
Status
Study Complete
Location
GSK Investigational Site
Corrientes, Corrientes, Argentina, W3400AMZ
Status
Study Complete
Location
GSK Investigational Site
Crestview Hills, Kentucky, United States, 41017
Status
Study Complete
Location
GSK Investigational Site
Danville, Pennsylvania, United States, 17822-4201
Status
Study Complete
Location
GSK Investigational Site
Deggingen, Baden-Wuerttemberg, Germany, 73326
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80218
Status
Study Complete
Location
GSK Investigational Site
Detroit, Michigan, United States, 48202
Status
Study Complete
Location
GSK Investigational Site
Dorsten, Nordrhein-Westfalen, Germany, 46282
Status
Study Complete
Location
GSK Investigational Site
Doylestown, Pennsylvania, United States, 18901
Status
Study Complete
Location
GSK Investigational Site
Durham, North Carolina, United States, 27710
Status
Study Complete
Location
GSK Investigational Site
Elizabeth, New Jersey, United States, 07202
Status
Study Complete
Location
GSK Investigational Site
Erie, Pennsylvania, United States, 16502
Status
Study Complete
Location
GSK Investigational Site
Eschweiler, Nordrhein-Westfalen, Germany, 52249
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45359
Status
Study Complete
Location
GSK Investigational Site
Franklin, Indiana, United States, 46131
Status
Study Complete
Location
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
Status
Study Complete
Location
GSK Investigational Site
Gainesville, Florida, United States, 32610
Status
Study Complete
Location
GSK Investigational Site
Gangnam-gu, Seoul, South Korea, 135-710
Status
Study Complete
Location
GSK Investigational Site
Garfield Heights, Ohio, United States, 44125
Status
Study Complete
Location
GSK Investigational Site
Garran, Australian Capital Territory, Australia, 2606
Status
Study Complete
Location
GSK Investigational Site
Gastonia, North Carolina, United States, 28054
Status
Study Complete
Location
GSK Investigational Site
Georgetown, Texas, United States, 78626
Status
Study Complete
Location
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom, G11 6NT
Status
Study Complete
Location
GSK Investigational Site
Goch, Nordrhein-Westfalen, Germany, 47574
Status
Study Complete
Location
GSK Investigational Site
Golden, Colorado, United States, 80401
Status
Study Complete
Location
GSK Investigational Site
Gosford, New South Wales, Australia, 2250
Status
Study Complete
Location
GSK Investigational Site
Grand Forks, North Dakota, United States, 58201
Status
Study Complete
Location
GSK Investigational Site
Grand Island, Nebraska, United States, 68803
Status
Study Complete
Location
GSK Investigational Site
Greenfield, Indiana, United States, 46140
Status
Study Complete
Location
GSK Investigational Site
Greenfield Park, Québec, Canada, J4V 2H1
Status
Study Complete
Location
GSK Investigational Site
Gueglingen, Baden-Wuerttemberg, Germany, 74363
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
Status
Study Complete
Location
GSK Investigational Site
Harker Heights, Texas, United States, 76548
Status
Study Complete
Location
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
Status
Study Complete
Location
GSK Investigational Site
Hartford, Connecticut, United States, 06067
Status
Study Complete
Location
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
Status
Study Complete
Location
GSK Investigational Site
Herford, Nordrhein-Westfalen, Germany, 32049
Status
Study Complete
Location
GSK Investigational Site
Hollywood, Florida, United States, 33023
Status
Study Complete
Location
GSK Investigational Site
Huntsville, Alabama, United States, 35801
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46256
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46260
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32207
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32216
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32258
Status
Study Complete
Location
GSK Investigational Site
Jacksonville Beach, Florida, United States, 32250
Status
Study Complete
Location
GSK Investigational Site
Jersey Shore, Pennsylvania, United States, 17740
Status
Study Complete
Location
GSK Investigational Site
Johnson City, Tennessee, United States, 37601
Status
Study Complete
Location
GSK Investigational Site
Joondalup, Western Australia, Australia, 6027
Status
Study Complete
Location
GSK Investigational Site
Kelowna, British Columbia, Canada, V1Y 1E4
Status
Study Complete
Location
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
Status
Study Complete
Location
GSK Investigational Site
Kirkland, Washington, United States, 98034
Status
Study Complete
Location
GSK Investigational Site
La Plata, Buenos Aires, Argentina, B1900AXI
Status
Study Complete
Location
GSK Investigational Site
Lafayette, Louisiana, United States, 70503
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89103
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89130
Status
Study Complete
Location
GSK Investigational Site
Lewistown, Pennsylvania, United States, 17044
Status
Study Complete
Location
GSK Investigational Site
Lienen-Kattenvenne, Nordrhein-Westfalen, Germany, 49536
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72204
Status
Study Complete
Location
GSK Investigational Site
Liverpool, New South Wales, Australia, 2170
Status
Study Complete
Location
GSK Investigational Site
Lomita, California, United States, 90717
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90024
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90036
Status
Study Complete
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40206
Status
Study Complete
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40213
Status
Study Complete
Location
GSK Investigational Site
Madera, California, United States, 93637
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
Status
Study Complete
Location
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116
Status
Study Complete
Location
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Status
Study Complete
Location
GSK Investigational Site
Matthews, North Carolina, United States, 28105
Status
Study Complete
Location
GSK Investigational Site
Melrose Park, Illinois, United States, 60160
Status
Study Complete
Location
GSK Investigational Site
Middleburg Heights, Ohio, United States, 44130
Status
Study Complete
Location
GSK Investigational Site
Monterrey NL, Nuevo León, Mexico, 64718
Status
Study Complete
Location
GSK Investigational Site
Motherwell, Lanarkshire, United Kingdom, ML1 3JX
Status
Study Complete
Location
GSK Investigational Site
Natal, Rio Grande do Norte, Brazil, 59020-100
Status
Study Complete
Location
GSK Investigational Site
Natick, Massachusetts, United States, 01760
Status
Study Complete
Location
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Status
Study Complete
Location
GSK Investigational Site
New Iberia, Louisiana, United States, 70563
Status
Study Complete
Location
GSK Investigational Site
New Westminister, British Columbia, Canada, V3L 3W4
Status
Study Complete
Location
GSK Investigational Site
New Westminster, British Columbia, Canada, V3L 3W4
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10001
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10021
Status
Study Complete
Location
GSK Investigational Site
Newark, Delaware, United States, 19718
Status
Study Complete
Location
GSK Investigational Site
Newcastle-upon-Tyne, United Kingdom, NE7 7DN
Status
Study Complete
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23502
Status
Study Complete
Location
GSK Investigational Site
Oakland, California, United States, 94611
Status
Study Complete
Location
GSK Investigational Site
Oakland, California, United States, 94612
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73120
Status
Study Complete
Location
GSK Investigational Site
Olympia, Washington, United States, 98502
Status
Study Complete
Location
GSK Investigational Site
Oxon Hill, Maryland, United States, 20745
Status
Study Complete
Location
GSK Investigational Site
Pelotas, Rio Grande Do Sul, Brazil, 96015-290
Status
Study Complete
Location
GSK Investigational Site
Petoskey, Michigan, United States, 49770
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
Status
Study Complete
Location
GSK Investigational Site
Ponte Verda, Florida, United States, 32081
Status
Study Complete
Location
GSK Investigational Site
Port Matilda, Pennsylvania, United States, 16870
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97219
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610000
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90880-480
Status
Study Complete
Location
GSK Investigational Site
Poway, California, United States, 92064
Status
Study Complete
Location
GSK Investigational Site
Pozuelo de Alarcón/Madrid, Spain, 28223
Status
Study Complete
Location
GSK Investigational Site
Prince Frederick, Maryland, United States, 20678
Status
Study Complete
Location
GSK Investigational Site
Providence, Rhode Island, United States, 02904
Status
Study Complete
Location
GSK Investigational Site
Ramos Mejia, Buenos Aires, Argentina, B1704ETD
Status
Study Complete
Location
GSK Investigational Site
Rapid City, South Dakota, United States, 57701
Status
Study Complete
Location
GSK Investigational Site
Renton, Washington, United States, 98057
Status
Study Complete
Location
GSK Investigational Site
Rhaunen, Rheinland-Pfalz, Germany, 55624
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23294
Status
Study Complete
Location
GSK Investigational Site
Rio de Janeiro, Rio De Janeiro, Brazil, 20551-030
Status
Study Complete
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2000CVD
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95819
Status
Study Complete
Location
GSK Investigational Site
Saint Charles-Borromee, Québec, Canada, J6E 6J2
Status
Study Complete
Location
GSK Investigational Site
Salisbury, North Carolina, United States, 28144
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78217
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78244
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92161
Status
Study Complete
Location
GSK Investigational Site
San Ramon, California, United States, 94582
Status
Study Complete
Location
GSK Investigational Site
San Sebastián de los Reyes/Madrid, Spain
Status
Study Complete
Location
GSK Investigational Site
Santa Ana, California, United States, 92705
Status
Study Complete
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 750 0922
Status
Study Complete
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500503
Status
Study Complete
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 8360160
Status
Study Complete
Location
GSK Investigational Site
Sayre, Pennsylvania, United States, 18840
Status
Study Complete
Location
GSK Investigational Site
Scarborough, Maine, United States, 04074
Status
Study Complete
Location
GSK Investigational Site
Scranton, Pennsylvania, United States, 18503
Status
Study Complete
Location
GSK Investigational Site
Scranton, Pennsylvania, United States, 18505
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98104
Status
Study Complete
Location
GSK Investigational Site
Sellersville, Pennsylvania, United States, 18960
Status
Study Complete
Location
GSK Investigational Site
Seongnam-si Gyeonggi-do, South Korea, 463-707
Status
Study Complete
Location
GSK Investigational Site
Sioux Falls, South Dakota, United States, 57105
Status
Study Complete
Location
GSK Investigational Site
Slidell, Louisiana, United States, 70458
Status
Study Complete
Location
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99204
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99207
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99208
Status
Study Complete
Location
GSK Investigational Site
Spring Valley, California, United States, 91978
Status
Study Complete
Location
GSK Investigational Site
Springfield, Massachusetts, United States, 01103
Status
Study Complete
Location
GSK Investigational Site
St Louis, Missouri, United States, 63110
Status
Study Complete
Location
GSK Investigational Site
St. Cloud, Minnesota, United States, 56303
Status
Study Complete
Location
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Status
Study Complete
Location
GSK Investigational Site
Sta Coloma de Gramanet (Barcelona), Spain, 08923
Status
Study Complete
Location
GSK Investigational Site
Statesville, North Carolina, United States, 28677
Status
Study Complete
Location
GSK Investigational Site
Sulzbach-Rosenberg, Bayern, Germany, 92237
Status
Study Complete
Location
GSK Investigational Site
Surrey, British Columbia, Canada, V3V 1N1
Status
Study Complete
Location
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil, 15015210
Status
Study Complete
Location
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil, 15090-000
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 04012-909
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 04012180
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 05403-000
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Talcahuano, Región Del Biobio, Chile, 427 0918
Status
Study Complete
Location
GSK Investigational Site
Thornton, Colorado, United States, 80229
Status
Study Complete
Location
GSK Investigational Site
Thousand Oaks, California, United States, 91360
Status
Study Complete
Location
GSK Investigational Site
Trois Rivières, Québec, Canada, G8T 7A1
Status
Study Complete
Location
GSK Investigational Site
Uijeongbu-si Kyonggi-do, South Korea, 480-717
Status
Study Complete
Location
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89081
Status
Study Complete
Location
GSK Investigational Site
Usti nad Orlici, Czech Republic, 562 18
Status
Study Complete
Location
GSK Investigational Site
Valparaiso, Indiana, United States, 46383
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Status
Study Complete
Location
GSK Investigational Site
Victoria, British Columbia, Canada, V8R 4R2
Status
Study Complete
Location
GSK Investigational Site
Walla Walla, Washington, United States, 99362
Status
Study Complete
Location
GSK Investigational Site
Wausau, Wisconsin, United States, 54401
Status
Study Complete
Location
GSK Investigational Site
Wenatchee, Washington, United States, 98801
Status
Study Complete
Location
GSK Investigational Site
West Des Moines, Iowa, United States, 50266
Status
Study Complete
Location
GSK Investigational Site
West Orange, New Jersey, United States, 07052
Status
Study Complete
Location
GSK Investigational Site
Westfield, New York, United States, 14787
Status
Study Complete
Location
GSK Investigational Site
Weyhe-Leeste, Niedersachsen, Germany, 28844
Status
Study Complete
Location
GSK Investigational Site
Wilkes-Barre, Pennsylvania, United States, 18702
Status
Study Complete
Location
GSK Investigational Site
Williamsville, New York, United States, 14221
Status
Study Complete
Location
GSK Investigational Site
Wilmington, North Carolina, United States, 28401
Status
Study Complete
Location
GSK Investigational Site
Winchester, Virginia, United States, 22601
Status
Study Complete
Location
GSK Investigational Site
Witten, Nordrhein-Westfalen, Germany, 58455
Status
Study Complete
Location
GSK Investigational Site
York, Pennsylvania, United States, 17403
Status
Study Complete
Location
GSK Investigational Site
jeonju-si, Jeollabuk-Do, South Korea, 561-712
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2013-17-10
Actual study completion date
2013-17-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website